CTIC News 3.04 06/12/2014 04:39:08 Cell Therapeutics (CTIC)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cell Therapeutics (CTIC) 3.04 $CTIC

CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates Randomized Phase 2 Trial Evaluating Tosedostat plus Cytarabine for Older Patients with AML or High-Risk MDS
PR Newswire - Thu Jun 12, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients with Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. The trial is being conducted by the National Cancer Research Institute Haematological Oncology Study Group under the sponsorship of Cardiff University. The trial management group is led by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University. Chroma Therapeutics Ltd., from whom CTI licensed tosedostat, is facilitating drug supply for the trial.

Insider Trading Alert - MWE, CPT And CTIC Traded By Insiders
at The Street - Mon Jun 09, 9:16AM CDT
Stocks with insider trader activity include MWE, CPT and CTIC

Cell Therapeutics reports rebranding of its corporate name
M2 - Fri May 30, 3:06AM CDT
Biopharmaceutical company Cell Therapeutics (NASDAQ:CTIC)(MTA:CTIC) announced on Friday a change in its corporate name to CTI BioPharma with immediate effect.

Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
PR Newswire - Fri May 30, 12:30AM CDT
Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-related cancers, today announced that it will change its corporate name to CTI BioPharma Corp. effective May 30, 2014. The Company's common stock will continue to trade under its current ticker symbol: "CTIC."

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell Therapeutics, Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Thu May 29, 11:52AM CDT
Levi & Korsinsky, LLP is investigating Cell Therapeutics, Inc. (NasdaqCM: CTIC) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company.

CollabRx's Mobile App Simplifies Cancer Treatment Options
ACCESSWIRE - Thu May 29, 9:46AM CDT
WHITEFISH, MT / May 29, 2014 / Treating cancer patients has become increasingly difficult given the condition's incredibly wide scope. For example, breast cancer can be treated in two very different ways depending on whether a patient is HER2 positive, triple negative, triple positive, or endocrine receptor positive. These types of tests and treatments are only increasing in scope as more genetic markers are discovered.

Cell Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4 at 11:30 a.m. PDT/2:30 p.m. EDT/8:30 p.m. CEST in New York.

Top Gainers on the Move -- Research on Aeropostale, FirstEnergy, Cell Therapeutics, and Dyax
PR Newswire - Wed May 28, 4:00AM CDT
The US markets saw a positive sentiment on Tuesday, May 27, 2014, with the NASDAQ Composite closing at 4,237.07, up 1.22%, the Dow Jones Industrial Average ending the session at 16,675.50, up 0.42% and the S&P 500 edging 0.60% higher to finish the trading session at 1,911.91. The gains were broad based as nine out of ten sectors ended the session in positive. A number of stocks saw large movements, including Aeropostale Inc. (NYSE: ARO), FirstEnergy Corp. (NYSE: FE), Cell Therapeutics Inc. (NASDAQ: CTIC) and Dyax Corp. (NASDAQ: DYAX). Free technical research on ARO, FE, CTIC and DYAX can be downloaded upon signing up at:

Stock to Watch: Cell Therapeutics Up 7.0% (CTIC)
Comtex SmarTrend(R) - Tue May 27, 11:41AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.0% to $3.06 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.3%) and outperformed the S&P 500 (7.0% to the S&P's 0.4%) during today's trading.

Why NTELOS, Cell Therapeutics, and Sanchez Energy Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 4:28PM CDT
When things are going right, not even mixed economic data can push the broad-based S&P 500 lower. The headline story that I would have expected to pressure the S&P 500 throughout the day was the weekly initial jobless claims figure....

Why Cell Therapeutics (CTIC) Stock Is Spiking Today
at The Street - Thu May 22, 11:27AM CDT
Cell Therapeutics (CTIC) is rocketing up today after being initiated with a 'buy' rating by analysts at Ladenburg (LTS).

Stock to Watch: Cell Therapeutics Up 12.2% (CTIC)
Comtex SmarTrend(R) - Thu May 22, 10:10AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 12.2% to $2.85 on 1.0x average daily volume. Cell Therapeutics has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (12.2% to the Dow's 0.2%) and outperformed the S&P 500 (12.2% to the S&P's 0.3%) during today's trading.

Zack's Research Initiates Coverage on Theralase With a Price Target of $1.00
ACCESSWIRE - Tue May 20, 9:22AM CDT
Theralase Lights Up Cancer Therapeutics

Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:

Cell Therapeutics Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 3:01PM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014.

PIXUVRI(R) Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire Europe - Tue Apr 29, 3:03AM CDT
- First and Only Approved Monotherapy in the EU for this Patient Population -

PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire - Tue Apr 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014
PR Newswire - Tue Apr 22, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:

Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 3:46PM CDT
The best thing about the stock market is that you can make money in  either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 0

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 18

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 19

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 370

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 358

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 81

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading

Top 5 Most Recently Viewed Articles

BETR Faces Securities Fraud Actions Post-Misleading Statements

Updated Category News Views 123

Unpacking the Legal Drama Around BETR The tale of Better Home & Finance Holding Company (BETR) is like a roadside crash you can't help but stare at. We're talking big, ugly losses and a chance for investors who got roughed up to throw some punches back with a securities fraud class action. The legal honchos at Howard G. Smith's law office are rallying the troops. If...

Continue Reading
Dorian LPG Faces Market Challenges But Holds Strong Financials

Updated Category News Views 133

Dorian LPG Stock Performance Overview In a challenging market environment, Dorian LPG Ltd. (NYSE: LPG) stock has recently touched a 52-week low, with shares falling to $24.86. This significant drop highlights a broader trend in the industry, as the company grapples with headwinds leading to a troubling one-year change of -38.78%. Investors are closely monitoring the stock...

Continue Reading
Copenhagen Airports A/S Annual General Meeting Announcement

Updated Category News Views 115

Upcoming Annual General Meeting of Copenhagen Airports A/S Shareholders are invited to participate in the Annual General Meeting of Copenhagen Airports A/S. This important event will take place on the scheduled date and time, providing an opportunity for stakeholders to engage with the management and stay informed about the company's direction. Notice of Meeting Details...

Continue Reading
Important Notice for Shareholders of KinderCare Learning

Updated Category News Views 131

Key Notice for KinderCare Learning Companies, Inc. Shareholders The Gross Law Firm has issued a crucial notice directed at shareholders of KinderCare Learning Companies, Inc. (NYSE: KLC) regarding a class action lawsuit. This communication is particularly relevant to those who acquired shares during the designated class period. Shareholders are strongly encouraged to make...

Continue Reading
Discover the New Romantic Getaway at Cicada Resort Bali Ubud

Updated Category News Views 350

Welcome to Cicada Resort Bali Ubud Cicada Resort Bali Ubud, Autograph Collection, located in Sebatu's tranquil environment, extends a warm invitation to travelers seeking a romantic retreat. The resort has recently become part of the prestigious Autograph Collection, contributing to its expanding presence in the hospitality space. Embrace Nature and Culture Just a short...

Continue Reading